A Phase 1, Open-label, Dose Escalation Study to Evaluate the Safety and Tolerability of Latanoprost Sustained Release (SR) Insert in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Trial Profile

A Phase 1, Open-label, Dose Escalation Study to Evaluate the Safety and Tolerability of Latanoprost Sustained Release (SR) Insert in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2014

At a glance

  • Drugs Latanoprost (Primary)
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Dec 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 07 Dec 2014 Planned End Date changed from 1 Dec 2015 to 1 Jun 2014 as reported by ClinicalTrials.gov record.
    • 07 Dec 2014 Planned primary completion date changed from 1 Sep 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top